Penumbra, Inc. (NYSE:PEN - Get Free Report) Director Bridget O'rourke sold 50 shares of the stock in a transaction on Monday, June 16th. The stock was sold at an average price of $259.78, for a total value of $12,989.00. Following the completion of the sale, the director now directly owns 5,373 shares in the company, valued at approximately $1,395,797.94. This represents a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Bridget O'rourke also recently made the following trade(s):
- On Thursday, May 15th, Bridget O'rourke sold 100 shares of Penumbra stock. The stock was sold at an average price of $286.15, for a total value of $28,615.00.
- On Tuesday, April 15th, Bridget O'rourke sold 50 shares of Penumbra stock. The shares were sold at an average price of $271.21, for a total transaction of $13,560.50.
Penumbra Stock Performance
Shares of NYSE PEN opened at $256.99 on Thursday. The company has a current ratio of 6.30, a quick ratio of 3.68 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $9.95 billion, a price-to-earnings ratio of 242.45, a price-to-earnings-growth ratio of 2.28 and a beta of 0.49. Penumbra, Inc. has a 12-month low of $148.00 and a 12-month high of $310.00. The firm has a 50 day moving average of $275.03 and a 200 day moving average of $267.39.
Penumbra (NYSE:PEN - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The company reported $0.83 EPS for the quarter, beating the consensus estimate of $0.66 by $0.17. The firm had revenue of $324.14 million for the quarter, compared to the consensus estimate of $315.72 million. Penumbra had a net margin of 3.41% and a return on equity of 11.14%. The company's revenue was up 16.3% on a year-over-year basis. During the same period last year, the firm earned $0.41 EPS. On average, research analysts anticipate that Penumbra, Inc. will post 3.67 earnings per share for the current year.
Hedge Funds Weigh In On Penumbra
Hedge funds have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. increased its position in Penumbra by 1.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 271,574 shares of the company's stock worth $64,493,000 after purchasing an additional 3,807 shares during the last quarter. Proficio Capital Partners LLC purchased a new stake in shares of Penumbra during the 4th quarter valued at about $3,553,000. HighTower Advisors LLC raised its position in shares of Penumbra by 3.2% during the 4th quarter. HighTower Advisors LLC now owns 5,980 shares of the company's stock valued at $1,420,000 after buying an additional 188 shares in the last quarter. Atria Investments Inc bought a new stake in Penumbra during the fourth quarter worth approximately $221,000. Finally, Envestnet Portfolio Solutions Inc. boosted its holdings in shares of Penumbra by 3.7% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 2,867 shares of the company's stock worth $681,000 after purchasing an additional 101 shares during the period. Hedge funds and other institutional investors own 88.88% of the company's stock.
Wall Street Analyst Weigh In
PEN has been the subject of several recent analyst reports. Morgan Stanley lifted their target price on shares of Penumbra from $240.00 to $260.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 19th. JPMorgan Chase & Co. boosted their price objective on shares of Penumbra from $230.00 to $285.00 and gave the stock an "overweight" rating in a report on Wednesday, February 19th. Canaccord Genuity Group increased their target price on Penumbra from $323.00 to $340.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. Wall Street Zen upgraded Penumbra from a "buy" rating to a "strong-buy" rating in a research note on Saturday, June 14th. Finally, Wells Fargo & Company boosted their target price on Penumbra from $305.00 to $315.00 and gave the stock an "overweight" rating in a research report on Thursday, April 24th. Three investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Penumbra has a consensus rating of "Moderate Buy" and a consensus price target of $302.40.
Read Our Latest Analysis on Penumbra
Penumbra Company Profile
(
Get Free Report)
Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
